Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Objective Response Rate”

56 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 56 results

Testing effectiveness (Phase 2)Ended earlyNCT01466868
What this trial is testing

Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B Cell Lymphoma
Centre Leon Berard 22
Testing effectiveness (Phase 2)Looking for participantsNCT06125834
What this trial is testing

Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy

Who this might be right for
Advanced Breast CancerObjective Response RateTrastuzumab Emtansine
The First Affiliated Hospital with Nanjing Medical University 36
Testing effectiveness (Phase 2)Ended earlyNCT00620100
What this trial is testing

To Determine the Objective Response Rate of 4 Cycles of Docetaxel + Anthracycline (Epirubicin or Doxorubicine) Followed by 4 Cycles of Docetaxel Single Agent

Who this might be right for
Breast Neoplasms
Sanofi 2
Not applicableUnknownNCT03892577
What this trial is testing

Real-world Study for Patients With Advanced Hepatobiliary Tumors

Who this might be right for
Objective Response RateProgression-free SurvivalOverall Survival+4 more
Peking Union Medical College Hospital 3,000
Testing effectiveness (Phase 2)UnknownNCT02124317
What this trial is testing

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer

Who this might be right for
Advanced Pancreatic Cancer
Chinese PLA General Hospital 60
Early research (Phase 1)Study completedNCT00481728
What this trial is testing

Evaluation of the Link Between Bladder Sensation and Changes in Skin Electrical Conductance and Heart Rate.

Who this might be right for
Overactive Bladder
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 28
Testing effectiveness (Phase 2)Study completedNCT01323400
What this trial is testing

Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)

Who this might be right for
GIST
Centre Leon Berard 81
Testing effectiveness (Phase 2)UnknownNCT05760196
What this trial is testing

Radiotherapy Combined With PD-1 Inhibitor and GM-CSF for Advanced Recurrent Metastatic Head and Neck Tumors

Who this might be right for
Objective Response Rate
Xiangpan Li 56
Testing effectiveness (Phase 2)Looking for participantsNCT06848842
What this trial is testing

Ivonescimab Plus Chemotherapy in Patients With Initially Unresectable Colorectal Cancer Liver Metastases

Who this might be right for
Colorectal Liver Metastases
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 40
Testing effectiveness (Phase 2)WithdrawnNCT01328106
What this trial is testing

Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma

Who this might be right for
GNA11 Mutation-positive Metastatic MelanomaGNAQ Mutation-positive Metastatic MelanomaCancer+1 more
GlaxoSmithKline
Testing effectiveness (Phase 2)Study completedNCT02083354
What this trial is testing

Study to Investigate the Objective Response Rate of Dabrafenib in Combination With Trametinib in Subjects With BRAF V600 Mutation-Positive Melanoma

Who this might be right for
CancerMelanoma
Novartis Pharmaceuticals 77
Testing effectiveness (Phase 2)UnknownNCT04664244
What this trial is testing

Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma

Who this might be right for
Recurrent Cervical CarcinomaRadiotherapyEpidermal Growth Factor Receptor+4 more
Lei Li 43
Testing effectiveness (Phase 2)Ended earlyNCT05300958
What this trial is testing

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Sun Yat-sen University 25
Early research (Phase 1)UnknownNCT04850560
What this trial is testing

Sequential Low-dose Decitabine With PD-1/CD28 CD19 CAR-T in Relapsed or Refractory B-cell Lymphoma

Who this might be right for
Objective Response Rate
Second Affiliated Hospital, School of Medicine, Zhejiang University 30
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Testing effectiveness (Phase 2)Study completedNCT00235937
What this trial is testing

Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex

Who this might be right for
Breast Cancer
AstraZeneca 45
Not applicableUnknownNCT05755009
What this trial is testing

High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor

Who this might be right for
Metastatic Cancer
Jiangxi Provincial Cancer Hospital 33
Not applicableUnknownNCT03336554
What this trial is testing

Epigenetic Biomarker for Osteosarcoma

Who this might be right for
Histologic Response (Tumor Necrosis Rate)Objective Response Rate for Neoadjuvant Chemotherapy, ORRProgression-free Survival, PFS+1 more
Peking University People's Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06520345
What this trial is testing

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Telix Pharmaceuticals (Innovations) Pty Limited 430
Testing effectiveness (Phase 2)UnknownNCT05582109
What this trial is testing

Envafolimab, Lenvatinib Combined With TACE in the Treatment of Unresectable Locally Advanced Hepatocellular Carcinoma

Who this might be right for
Objective Response Rate (ORR)
Tianjin Medical University Cancer Institute and Hospital 30
Load More Results